FARMAKOTERAPIYa VTORIChNOGO OSTEOARTROZA NA FONE KOMORBIDNOY PATOLOGII
- Authors: Starodubtseva I.A1
-
Affiliations:
- Issue: No 19 (2015)
- Pages: 43-46
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/288347
- ID: 288347
Cite item
Open Access
Access granted
Abstract
The article describes the results of a study of clinical efficacy of interleukin-1 inhibitor in the treatment of secondary osteoarthrosis in patients with rheumatoid arthritis. Dynamics of parameters of the general state of the patient, according to patient’s and doctor’s opinion, as well as a decrease in the duration of morning stiffness indicate the benefits of using of interleukin-1 inhibitor in treatment of not only secondary OA, but also the underlying disease.
Full Text
References
- Гордеев А.В., Галушко Е.А., Насонов Е.Л. Концепция мультиморбидности в ревматологической практике. Научнопрактическая ревматология. 2014; 4: 362-65.
- Bijlsma J.W., Berenbaum F., Lafeber F.P. Osteoarthritis: an update with relevance for clinical practice. Lancet. 2011; 377: 2115-26.
- Chikanza I.C., Clarke B., Hopkins R. A comparative study of the efficacy and toxicity of etodolac and naproxen in the treatment of osteoarthritis. Br. J. Clin. Pract. 1994; 48: 67-9.
- Pelletier J. P., Me Collum R., DiBattista J., Loose L. D., Cloutier J. M., Martel-Pelletier J. Regulation of human normal and osteoarthritic chondrocyte interleukin-I receptor by antirheumatic drugs. Arthritis Rheum. 1993; 36: 1-2.
- Martell-Palletier J. Biochemical factors injointtissue degradation in osteoarthritis. Osteoarthritis. Clinical and experimental aspects. Springer. 1999; 156-87.
- Martel-Pelletier J. Inflammatory factors involved in Osteoarthritis. In: Osteoarthritis, Inflammation and Degradation: A Continuum. IOS Press. 2007; 3: 3-13.
- Бадокин В.В. Значение воспаления в развитии и течении остеоартроза. Consilium Medicum. 2009; 11(9): 91-5.
- Martell-Pelletier J. In vitro effects of Diacerhein and Rhein on IL-1 and TNF-ß systems in human osteoarthritis synovium and chondrocytes. J. Rheumatol. 1998; 25: 735-62.
- Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., Healey L.A., Kaplan S.R., Liang M.H., Luthra H.S., et al. American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheumatism. 1988; 31: 315-24.
- Aletaha D., Neogi T., Silman A.J., et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/ European League against Rheumatism collaborative initiative. Ann. Rheum. Dis. 2010; 69: 1580-88.
- Restrictions of the use of diacerein - containing medicines. Restrictions intended to limit risks of severe diarrhoea and effects on the liver. 4 September 2014; EMA/544268/2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Diacerein/European_Commission_final_decision/WC500173144.pdf (дата обращения 15.09.2014).
- Bartels E.M., Bliddal H., Schondorff P.K., Altman R.D., Zhang W., Christensen R. Symptomatic efficacy and safety of diacerhein in the treatment of osteoarthritis: a meta-analysis of randomized placebo-controlled trials. Osteoarthritis Cartilage. 2010; 18(3): 289-96.
- Pavelka K., Trc T., Karpas K., Vitek P., Sedlackova M., Vlasakova V., Böhmova J., Rovensky J. The efficacy and safety of Diacerhein in the treatment of painful osteoarthritis of the knee: a randomised, multicentre, double-blind, placebocontrolled study with primery end points at two months after the end of a three-month treatment period. Arthr. Rheum. 2007; 56: 4055-64.
- Наумов А.В. Эффективность и безопасность диацереина в терапии хронической боли при остеоартрите у пациентов с сердечно-сосудистой коморбидностью и противопоказаниями к НПВП. Поликлиника. 2015; 4: 1-6.
Supplementary files
